Analyzing GB Sciences (OTCMKTS:GBLX) and Hyperion DeFi (NASDAQ:HYPD)

Hyperion DeFi (NASDAQ:HYPD) and GB Sciences (OTCMKTS:GBLX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Profitability

This table compares Hyperion DeFi and GB Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
GB Sciences	N/A	N/A	N/A

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 13.6% of GB Sciences shares are held by institutional investors. 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Hyperion DeFi and GB Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	1	1	2.25
GB Sciences	0	0	0	0	0.00

Hyperion DeFi currently has a consensus price target of $5.88, suggesting a potential upside of 65.96%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than GB Sciences.

Valuation and Earnings

This table compares Hyperion DeFi and GB Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04 million	51.45	-$45.31 million	($9.95)	-0.36
GB Sciences	N/A	N/A	N/A	($0.30)	0.00

GB Sciences has lower revenue, but higher earnings than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than GB Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Hyperion DeFi beats GB Sciences on 7 of the 11 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About GB Sciences

GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.